bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
Business Wire•13/10/2026•08:00 ET
0
Key Highlights
- ➤CHEST 2026 data show sputum test detects cellular and soluble inflammatory biomarkers
- ➤Test measures TSLP, CRLF2, IL4-Ra, and IL-5 biologic drug targets
- ➤bioAffinity advances investigational asthma and COPD inflammation test using flow cytometry and AI
- ➤Global asthma therapeutics market projected to reach $47.6 billion by 2034
- ➤CyPath Lung previously demonstrated 92% sensitivity and 99% negative predictive value
Expert Statements
Gordon Downie, Chief Medical Officer of bioAffinity Technologies
“Lung inflammation in asthma is complex and heterogeneous, and clinicians need better tools to characterize what is happening in the lung and understand differences among patients,”
Gordon Downie, Chief Medical Officer of bioAffinity Technologies
“We believe this research represents an important step toward a better understanding of distinct types of lung inflammation and targeted treatment specific to each patient.”
William Bauta, Chief Science Officer of bioAffinity Technologies
“Our research shows the potential to measure cellular and protein features directly from sputum, including selected targets associated with specific biologic drugs,”
William Bauta, Chief Science Officer of bioAffinity Technologies
“We believe this test could provide a more detailed picture of lung inflammation and, with further study, help doctors discern among treatment options and track inflammatory changes in the lung over time.”
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets
Get started
Create a free account to read the full story.